Intraperitoneal administration of LDN-193189 could partially prevent heterotopic ossification without inducing osteopenia or bone fractures in a mouse model of FOP characterised by a constitutively active version of ALK2 [176]. This evidence concerns the gene ACVR1 and fibrodysplasia ossificans progressiva.